All-trans Retinoic Acid Exerts Selective Anti-Flt3-itd Acute Myeloid Leukemia Efficacy Through Downregulating Chk1 Kinase.

Wenliang Wang,Zongru Jiang,Li Wang,Aoli Wang,Juan Liu,Cheng Chen,Kailin Yu,Fengming Zou,Wenchao Wang,Jing Liu,Qingsong Liu
DOI: https://doi.org/10.1016/j.canlet.2019.12.045
IF: 9.756
2020-01-01
Cancer Letters
Abstract:All-trans retinoic acid (ATRA) is known to be a potent inhibitor of FLT3-ITD acute myeloid leukemia (AML) cells, although the exact mechanism remains unclear. In this work, we report that ATRA causes fatal mitotic catastrophe in FLT3-ITD AML cells by degrading Chk1 kinase, and therefore preventing DNA damage repair. In order to explore a further enhancement in the inhibitory effect of ATRA on FLT3-ITD AML cells, we investigated the suitability of a combination of ATRA and DNA damage drug SN38. In vitro experiments showed that this combinatorial approach effectively inhibited the proliferation of FLT3-ITD cells and induced cell apoptosis in AML. In vivo experiments confirmed that the combination could substantially improve the anti-tumor effect of SN38. Taken together, our results indicate that ATRA down-regulates Chk1 in FLT3-ITD AML cells, and the combination of ATRA and SN38 significantly improves the anti-tumor effect of either ATRA or SN38 when used alone.
What problem does this paper attempt to address?